000285101 001__ 285101
000285101 005__ 20240229155101.0
000285101 0247_ $$2doi$$a10.1111/bcp.15924
000285101 0247_ $$2pmid$$apmid:37815301
000285101 0247_ $$2ISSN$$a0306-5251
000285101 0247_ $$2ISSN$$a1365-2125
000285101 0247_ $$2altmetric$$aaltmetric:155352621
000285101 037__ $$aDKFZ-2023-02225
000285101 041__ $$aEnglish
000285101 082__ $$a610
000285101 1001_ $$0P:(DE-He78)69f4086396e9a4830b9bdb751b68f2a6$$aLonguespée, Rémi$$b0$$eFirst author$$udkfz
000285101 245__ $$aTherapeutic drug monitoring of osimertinib in non-small cell lung cancer and short bowel syndrome: A case report.
000285101 260__ $$aOxford$$bWiley-Blackwell$$c2024
000285101 3367_ $$2DRIVER$$aarticle
000285101 3367_ $$2DataCite$$aOutput Types/Journal article
000285101 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1703857087_1122
000285101 3367_ $$2BibTeX$$aARTICLE
000285101 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285101 3367_ $$00$$2EndNote$$aJournal Article
000285101 500__ $$aCase report / 2024 Jan;90(1):344-349 / #EA:B350#
000285101 520__ $$aShort bowel syndrome (SBS) following extensive intestinal resection is often characterized by impaired absorption of orally administered drugs, including tyrosine kinase inhibitors (TKI). We report the case of a patient with EGFR-mutated non-small cell lung carcinoma treated with 80 mg/day of the TKI osimertinib who achieved partial response of the tumour, but was subsequently subjected to a double-barrelled jejunostomy due to ileus. Due to the development of SBS after the bypass surgery, plasma concentrations of osimertinib were monitored using mass spectrometry. The therapeutic drug monitoring confirmed a malabsorption of osimertinib in the patient (108 ng/mL, which is below the 5th percentile of the expected plasma concentration) and was useful to guide adjustments of TKI dosing in order to achieve adequate blood levels (161 ng/mL after increase of the dose to 120 mg/day) in order to maintain tumour control.
000285101 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000285101 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000285101 650_7 $$2Other$$aLC-MS/MS
000285101 650_7 $$2Other$$aMALDI-MS/MS
000285101 650_7 $$2Other$$anon-small cell lung cancer
000285101 650_7 $$2Other$$aosimertinib
000285101 650_7 $$2Other$$ashort bowel syndrome
000285101 650_7 $$2Other$$atherapeutic drug monitoring
000285101 7001_ $$aKunz, Julia$$b1
000285101 7001_ $$aFresnais, Margaux$$b2
000285101 7001_ $$aFoerster, Kathrin I$$b3
000285101 7001_ $$aBurhenne, Jürgen$$b4
000285101 7001_ $$aThomas, Michael$$b5
000285101 7001_ $$aKazdal, Daniel$$b6
000285101 7001_ $$aStenzinger, Albrecht$$b7
000285101 7001_ $$aChristopoulos, Petros$$b8
000285101 7001_ $$00000-0003-0672-6876$$aHaefeli, Walter E$$b9
000285101 773__ $$0PERI:(DE-600)1498142-7$$a10.1111/bcp.15924$$gp. bcp.15924$$n1$$p344-349$$tBritish journal of clinical pharmacology$$v90$$x0306-5251$$y2024
000285101 909CO $$ooai:inrepo02.dkfz.de:285101$$pVDB
000285101 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)69f4086396e9a4830b9bdb751b68f2a6$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000285101 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000285101 9141_ $$y2023
000285101 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2023-10-21$$wger
000285101 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000285101 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000285101 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-21
000285101 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000285101 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000285101 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000285101 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000285101 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000285101 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000285101 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000285101 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-21
000285101 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRIT J CLIN PHARMACO : 2022$$d2023-10-21
000285101 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000285101 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000285101 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-21
000285101 9201_ $$0I:(DE-He78)B350-20160331$$kB350$$lMetabolischer Crosstalk bei Krebserkrankungen$$x0
000285101 9200_ $$0I:(DE-He78)B350-20160331$$kB350$$lMetabolischer Crosstalk bei Krebserkrankungen$$x0
000285101 980__ $$ajournal
000285101 980__ $$aVDB
000285101 980__ $$aI:(DE-He78)B350-20160331
000285101 980__ $$aUNRESTRICTED